Exhibit 10.2
REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT
THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2021, is made and entered into by and among Lazard Healthcare Acquisition Corp. I, a Cayman Islands exempted company (the “Company”), LHACo 1 LLC, a Delaware series limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, together with the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “Holder” and collectively the “Holders”).
RECITALS
WHEREAS, the Sponsor currently owns 7,187,500 Class B ordinary shares of the Company, par value $0.0001 per share (the “Class B Ordinary Shares”) (up to 937,500 of which are subject to partial or complete forfeiture if the Underwriters’ over-allotment option in connection with the Company’s initial public offering is not exercised in full), and the other Holders currently own an aggregate of [●] Class B Ordinary Shares, which were received from the Sponsor pursuant to the terms of certain Director Share Transfer Agreements entered into by the Sponsor with each of the Company’s independent director nominees;
WHEREAS, the Class B Ordinary Shares are convertible into Class A ordinary shares of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), at the time of the initial Business Combination on a one-for-one basis, subject to adjustment, on the terms and conditions provided in the Company’s amended and restated memorandum and articles of association, as may be amended from time to time;
WHEREAS, the Company and the Sponsor entered into that certain Private Placement Warrants Purchase Agreement, pursuant to which the Sponsor agreed to purchase 5,500,000 warrants (or up to 6,000,000 warrants if the Underwriters’ over-allotment option in connection with the Company’s initial public offering is exercised in full), each exercisable to purchase one Class A Ordinary Share at $11.50 per share, subject to adjustment (the “Private Placement Warrants”), in a private placement transaction occurring simultaneously with the closing of the Company’s initial public offering;
WHEREAS, in order to finance the Company’s transaction costs in connection with its search for, and consummation of, an initial Business Combination, in the future the Sponsor or its affiliates may, but are not obligated to, loan the Company funds as the Company may require, of which up to $2,000,000 of such loans may be convertible at the option of the lender into an additional 1,333,333 Private Placement Warrants, at a price of $1.50 per warrant (the “Working Capital Warrants”); and
WHEREAS, the Company and the Holders desire to enter into this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
ARTICLE 1
DEFINITIONS
1.1 Definitions. The terms defined in this Article I shall, for all purposes of this Agreement, have the respective meanings set forth below:
“Adverse Disclosure” shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the chief executive officer, chief financial officer or executive chairman of the Company, after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary